(Q43955529)

28 November 2017

title

Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy (English)

1 reference

28 November 2017

1 reference

Yoh Miyashita

1

1 reference

28 November 2017

Kohji Shirai

2

1 reference

28 November 2017

Yoshiaki Itoh

3

1 reference

28 November 2017

Hidehisa Sasaki

4

1 reference

28 November 2017

Mitsuya Totsuka

5

1 reference

28 November 2017

Takeyoshi Murano

6

1 reference

28 November 2017

Hitoshi Watanabe

7

1 reference

28 November 2017

publication date

1 June 2002

1 reference

Diabetes Research and Clinical Practice

28 November 2017

published in

1 reference

28 November 2017

volume

56

1 reference

28 November 2017

issue

3

1 reference

28 November 2017

page(s)

181-187

1 reference

Lipolytic enzymes and plasma lipoprotein metabolism

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900369-2

7 January 2021

Regulation of the synthesis, processing and translocation of lipoprotein lipase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900369-2

7 January 2021

Transport of lipoprotein lipase across endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900369-2

7 January 2021

Fatty acid control of lipoprotein lipase: a link between energy metabolism and lipid transport

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900369-2

7 January 2021

Lipoprotein lipase mass and activity in severe hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900369-2

7 January 2021

Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900369-2

7 January 2021

Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900369-2

7 January 2021

The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900369-2

7 January 2021

Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900369-2

7 January 2021

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900369-2

7 January 2021

Clinical efficacy of the direct assay method using polymers for serum high density lipoprotein cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900369-2

7 January 2021

10.1016/S0168-8227(01)00369-2

Identifiers

DOI

1 reference

28 November 2017

1 reference